New Clinical Guidelines for the Treatment of Brain Tumors Published
Researchers from the Medical University of Vienna have published clinical recommendations for the treatment and diagnosis of brain metastases from solid tumors. These joint recommendations include the latest methods for diagnosis, treatment, prevention and follow-up for brain metastases. They were drafted in partnership with experts from the European Society for Medical Oncology and the European Association of Neuro-Oncology.
The experts note that these guidelines are a valuable source of information for physicians and other service providers, as well as patients and their families. The guidelines were published in the “Annals of Oncology” journal.
Brain metastasis is common in cancer patients. For most patients, the objective of brain metastases treatment is to delay or prevent neurological deterioration to help prolong survival and improve the quality of life of patients. Of this number, only a few patients, especially those with small lesions, may experience total recovery.
Matthias Preusser, the lead author of the guidelines and the current president of the European Association of Neuro-Oncology, stated that the researchers had made significant progress in the biological treatment and diagnosis of brain metastases, as well as understanding brain metastases better. Preusser, who is also head of the division of oncology head under the Department of Internal Medicine at the Medical University of Vienna, explained that the examination of tumor tissues was becoming important in the field of diagnostics as molecular analysis of cerebrospinal fluid or blood samples usually revealed genetic changes. which could be utilized as a basis for choosing targeted treatments.
Anna Berghoff, co-author of the study, explained that modern cancer treatments were personalized, noting that individually targeted immunotherapies and treatments were a therapeutic approach with great potential.
Preusser also explained that in the past few years, distinguishable successes had been achieved in treatment, as response rates were substantially increased in the treatment of brain metastases caused by skin cancer. He then noted that more than 55% of patients suffering from asymptomatic brain metastases of skin cancer could achieve sustained remissions in the brain after undergoing immunotherapy.
In addition to this, response rates above 50% had also been achieved with individualized treatments for brain metastases of breast cancer and lung cancer, particularly when gene amplifications or oncogenic mutations were present in the tumors. Preusser further explains that brain metastases were still one of the most severe situations in oncology. However, he asserted that advances in oncology based off of biological research were leading to better and longer survival for various patients, noting that these successes provided researchers with motivation to carry on with their research.
As brain diagnostics advance through the efforts of companies such as Brain Scientific Inc. (OTCQB: BRSF), it is likely to get easier to catch neurological conditions early when chances of complete healing are higher.
NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Researchers from the Medical University of Vienna have published clinical recommendations for the treatment and diagnosis of brain metastases from solid tumors. These joint recommendations include the latest methods for diagnosis, treatment, prevention and follow-up for brain metastases. They were drafted in partnership with experts from the European Society for Medical Oncology and the European Association of Neuro-Oncology.
The experts note that these guidelines are a valuable source of information for physicians and other service providers, as well as patients and their families. The guidelines were published in the “Annals of Oncology” journal.
Brain metastasis is common in cancer patients. For most patients, the objective of brain metastases treatment is to delay or prevent neurological deterioration to help prolong survival and improve the quality of life of patients. Of this number, only a few patients, especially those with small lesions, may experience total recovery.
Matthias Preusser, the lead author of the guidelines and the current president of the European Association of Neuro-Oncology, stated that the researchers had made significant progress in the biological treatment and diagnosis of brain metastases, as well as understanding brain metastases better. Preusser, who is also head of the division of oncology head under the Department of Internal Medicine at the Medical University of Vienna, explained that the examination of tumor tissues was becoming important in the field of diagnostics as molecular analysis of cerebrospinal fluid or blood samples usually revealed genetic changes. which could be utilized as a basis for choosing targeted treatments.
Anna Berghoff, co-author of the study, explained that modern cancer treatments were personalized, noting that individually targeted immunotherapies and treatments were a therapeutic approach with great potential.
Preusser also explained that in the past few years, distinguishable successes had been achieved in treatment, as response rates were substantially increased in the treatment of brain metastases caused by skin cancer. He then noted that more than 55% of patients suffering from asymptomatic brain metastases of skin cancer could achieve sustained remissions in the brain after undergoing immunotherapy.
In addition to this, response rates above 50% had also been achieved with individualized treatments for brain metastases of breast cancer and lung cancer, particularly when gene amplifications or oncogenic mutations were present in the tumors. Preusser further explains that brain metastases were still one of the most severe situations in oncology. However, he asserted that advances in oncology based off of biological research were leading to better and longer survival for various patients, noting that these successes provided researchers with motivation to carry on with their research.
As brain diagnostics advance through the efforts of companies such as Brain Scientific Inc. (OTCQB: BRSF), it is likely to get easier to catch neurological conditions early when chances of complete healing are higher.
NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
